Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension

Pharmacogenetics and Genomics

Volumn 15, Issue 1, 2005, Pages 7-13

  King, Lorraine M ^a   Gainer, James V ^b   David, Gloria L ^a   Dai, Ding ^a   Goldstein, Joyce A ^a   Brown, Nancy J ^b   Zeldin, Darryl C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

arachidonic acid; cis epoxyeicosatrienoic acids; cytochrome P450; eicosanoid; hypertension

Indexed keywords

ARACHIDONATE EPOXYGENASE; ARGININE; CYP2C8 PROTEIN, HUMAN; CYTOCHROME P450; ELECTROLYTE; LYSINE; OXYGENASE; UNSPECIFIC MONOOXYGENASE; CYTOCHROME P450 2C8; CYTOCHROME P450 2J2; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CHEMISTRY; ETHNOLOGY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PHARMACOGENETICS; RISK; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AFRICAN AMERICAN; AMINO ACID SEQUENCE; BLOOD PRESSURE; BODY MASS; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; FAMILY HISTORY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; UNITED STATES;

ADULT; ALLELES; ARGININE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ELECTROLYTES; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LINKAGE DISEQUILIBRIUM; LYSINE; MALE; MIDDLE AGED; ODDS RATIO; OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEX FACTORS;

EID: 85047278388     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01213011-200501000-00002     Document Type: Article

References (47)

1. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000; 41:163-181.
2. Roman RJ, Maier KG, Sun CW, Harder DR, Alonso-Galicia M. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 2000; 27:855-865.
3. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001; 12:12.
4. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996; 271:3460-3468.
5. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996; 330:87-96.
6. Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 1995; 322:76-86.
7. Fisslthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R, et al. Nifedipine increases cytochrome P4502C expression and endothelium- derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 2000; 36:270-275.
8. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285:1276-1279.
9. Rifkind AB, Lee C, Chang TK, Waxman DJ. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995; 320:380-389.
10. Daikh BE, Laethem RM, Koop DR. Stereoselective epoxidation of arachidonic acid by cytochrome P-450s 2CAA and 2C2. J Pharmacol Exp Ther 1994; 269:1130-1135.
11. Ma J, Qu W, Scarborough PE, Tomer KB, Moomaw CR, Maronpot R, et al. Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. J Biol Chem 1999; 274:17777-17788.
12. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997; 272:12551-12559.
13. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401:493-497.
14. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78:415-423.
15. McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol 1991; 31:339-369.
16. Fleming I, Busse R. Vascular cytochrome P450 in the regulation of renal function and vascular tone: EDHF, superoxide anions and blood pressure. Nephrol Dial Transplant 2001; 16:1309-1311.
17. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
18. Oyekan AO, Youseff T, Fulton D, Quilley J, McGiff JC. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest 1999; 104:1131-1137.
19. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994; 94:2414-2420.
20. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 1999; 104:751-760.
21. Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, Badr KF. Cytochrome P-450 arachidonate metabolites in rat kidney: characterization and hemodynamic responses. Am J Physiol 1990; 258:F781-F789.
22. Katoh T, Takahashi K, Capdevila J, Karara A, Falck JR, Jacobson HR, et al. Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney. Am J Physiol 1991; 261:F578-F586.
23. Zhu D, Bousamra M, Zeldin DC, Falck JR, Townsley M, Harder DR, et al. Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 2000; 278:L335-L343.
24. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, et al. Increased CYP2 J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 2000; 57:1011-1020.
25. Catella F, Lawson J, Braden G, Fitzgerald DJ, Shipp E, FitzGerald GA. Biosynthesis of P450 products of arachidonic acid in humans: increased formation in cardiovascular disease. Adv Prostaglandin Thromboxane Leukot Res 1991; 21A:193-196.
26. Levere RD, Martasek P, Escalante B, Schwartzman ML, Abraham NG. Effect of heme arginate administration on blood pressure in spontaneously hypertensive rats. J Clin Invest 1990; 86:213-219.
27. Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere RD, Schwartzman ML. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 1989; 243:388-390.
28. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.
29. King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002; 61:840-852.
30. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase, CYP2J2. Circulation 2004; 110:2132-2136.
31. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003; 13:715-720.
32. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York, New York: Wiley; 1987.
33. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15:273-280.
34. Ingelman-Sundberg M. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001; 120:259-268.
35. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22:298-305.
36. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360:1155-1162.
37. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000; 10:279-290.
38. Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension 2003; 42:775-780.
39. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000; 275:40504-40510.
40. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 87:992-998.
41. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002; 39:690-694.
42. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension 2003; 41:709-714.
43. Pucci L, Lucchesi D, Chirulli V, Penno G, Johansson I, Gervasi P, et al. Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus. Am J Pharmacogenomics 2003; 3:355-358.
44. Cardon LR, Bell JI. Association study designs for complex diseases. Nature Rev Genet 2001; 2:91-99.
45. Freimer N, Sabatti C. The use of pedigree, sib-pair and association studies of common diseases for genetic mapping and epidemiology. Nature Genet 2004; 36:1045-1051.
46. Krawczak M, Boehringer S, Epplen JT. Correcting for multiple testing in genetic association studies: the legend lives on. Hum Genet 2001; 109:566-567.
47. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nature Genet 2003; 33:177-182.